Ongoing Clinical Trials for Pyrexia
This article provides information about ongoing clinical trials for pyrexia, a condition characterized by fever. Currently, there is 1 active clinical trial investigating the optimal timing for pneumococcal vaccination in adults experiencing fever who are at risk for pneumococcal infections. The trial is being conducted in France and aims to determine whether the 20-valent pneumococcal vaccine is equally effective when given during a febrile illness compared to after the fever has resolved.
Clinical trial locations
Study on the Safety and Immune Response of the 20-Valent Pneumococcal Vaccine in Adults with Fever and High Risk for Pneumococcal Infection
This clinical trial is examining how the 20-valent pneumococcal conjugate vaccine (PCV-20), also known as Prevenar 20, works in adults who have fever and are at medium or high risk for pneumococcal infections. Pneumococcal bacteria can cause serious illnesses including pneumonia, meningitis, and bloodstream infections. The vaccine is designed to protect against 20 different types of these bacteria.
Main focus: The trial aims to compare whether the vaccine produces a similar immune response when given during an acute febrile illness (when someone has a sudden fever) versus when it is given 15 to 58 days after the fever has gone away. Researchers will monitor the immune response one month after vaccination and track any side effects or reactions that occur within a month of receiving the vaccine. The study will also follow participants for one year to observe respiratory infections and confirmed pneumococcal infections, as well as examine gut bacteria diversity and specific immune markers.
Who can participate: Adults between 18 and 84 years old who meet the following criteria:
- Have had a body temperature of at least 38°C (100.4°F) measured at least twice before joining the study
- Have been hospitalized for more than 24 hours
- Have at least one health condition that puts them at medium or high risk for pneumococcal infection, such as:
- Medium risk conditions: chronic heart failure, long-term breathing problems like COPD or severe asthma, long-term kidney or liver problems, diabetes requiring treatment, certain heart defects, or fluid leaking from around the brain
- High risk conditions: having no spleen or a poorly functioning spleen, inherited immune system problems, living with HIV, having had an organ transplant, taking immune-suppressing medications for chronic autoimmune diseases, or having nephrotic syndrome
- Have social security coverage and provide signed informed consent
Who cannot participate: The trial excludes patients who have already been vaccinated against pneumococcal infections. It also has specific timing requirements based on whether vaccination occurs during fever or after fever resolution.
Investigational drug: The 20-valent pneumococcal conjugate vaccine (PCV-20) is administered as an intramuscular injection using a pre-filled syringe. This vaccine helps the body build immunity against 20 different types of pneumococcal bacteria, reducing the risk of serious infections. The trial is testing whether the vaccine works equally well when given during a fever compared to after the fever has subsided.
Study process: Participants are randomly assigned to one of two groups. One group receives the vaccine while experiencing fever, and the other group receives it 15 to 58 days after their fever has resolved. The immune response is evaluated at one month and again at one year after vaccination. Safety is monitored by tracking any adverse events, local reactions at the injection site, or systemic effects related to the vaccination.
Summary
Currently, there is one ongoing clinical trial focused on vaccination timing in adults with fever who are at risk for pneumococcal infections. This trial, conducted in France, is investigating whether the 20-valent pneumococcal vaccine can be safely and effectively administered during an acute febrile illness rather than waiting for the fever to resolve. The study is particularly relevant for adults with chronic health conditions that increase their risk of serious pneumococcal infections, including heart disease, lung disease, diabetes, and compromised immune systems. This research may help inform vaccination strategies for vulnerable populations experiencing fever, potentially allowing for more flexible timing of this important preventive measure.
